Plan B's Problem With Heavier Women Isn't News in Europe

Tablet production at Teva Pharmaceutical Industries Ltd.'s headquarters in Jerusalem, Israel in 2011 Photograph by Adam Reynolds/Bloomberg

When Teva Pharmaceuticals gained exclusive rights from the Food and Drug Administration to market Plan B One-Step as an over-the-counter emergency contraceptive for “all women of child-bearing potential” this year, advocates considered it a victory for reproductive rights. But a new labeling change for an identical drug in Europe now raises the prospect that the treatment may not work for women weighing more than 165 pounds.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.